Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma

Autor: Yukihiko Sonoda, Ozawa T, Kd, Aldape, Df, Deen, Ms, Berger, Ro, Pieper

Publikováno v: Europe PubMed Central

Human malignant gliomas are thought to develop as the result of stepwise accumulations of multiple genetic alterations. Recently, we showed that E6/E7-mediated inactivation of p53/pRb, ras pathway activation (initiated by expression of mutant H-Ras),

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::32834d85ed2111e32819b35ded248dd5
https://pubmed.ncbi.nlm.nih.gov/11559533

Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report

Autor: Sm, Chang, Jg, Kuhn, Rizzo J, Hi, Robins, Sc, Schold, Am, Spence, Ms, Berger, minesh mehta, Me, Bozik, Pollack I, Gilbert M, Fulton D, Rankin C, Malec M, Md, Prados

Publikováno v: Scopus-Elsevier
Europe PubMed Central

PURPOSE To determine the maximum-tolerated dose (MTD) of paclitaxel administered as a 3-hour infusion in patients with recurrent malignant glioma. PATIENTS AND METHODS Patients were stratified by starting dose of paclitaxel and concurrent anticonvuls

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9e8ecac749ebe86ab88a8c422b165fe
https://pubmed.ncbi.nlm.nih.gov/9626220

Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells

Autor: Yuichi Hirose, Ms, Berger, Ro, Pieper

Publikováno v: Publons

Temozolomide (TMZ) produces O(6)-methylguanine in DNA, which in turn mispairs with thymine, triggering futile DNA mismatch repair (MMR) and ultimately cell death. We found previously that in p53-proficient human glioma cells, TMZ-induced futile DNA M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::86dff2512b26dbbf6a4d23261c9f4c73
https://publons.com/publon/19878763/

Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses.

Autor: Lucas CG; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Pathology, University of California, San Francisco, California, USA.; Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA., Al-Adli NN; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Neurological Surgery, University of California, San Francisco, California, USA., Young JS; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Neurological Surgery, University of California, San Francisco, California, USA., Gupta R; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Pathology, University of California, San Francisco, California, USA., Morshed RA; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Neurological Surgery, University of California, San Francisco, California, USA., Wu J; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Pathology, University of California, San Francisco, California, USA., Ravindranathan A; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Pathology, University of California, San Francisco, California, USA., Shai A; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Neurological Surgery, University of California, San Francisco, California, USA., Oberheim Bush NA; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Division of Neuro-Oncology, Department of Neurological Surgery, University of California, San Francisco, California, USA.; Department of Neurology, University of California, San Francisco, California, USA., Taylor JW; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Division of Neuro-Oncology, Department of Neurological Surgery, University of California, San Francisco, California, USA.; Department of Neurology, University of California, San Francisco, California, USA., de Groot J; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Division of Neuro-Oncology, Department of Neurological Surgery, University of California, San Francisco, California, USA.; Department of Neurology, University of California, San Francisco, California, USA., Villanueva-Meyer JE; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Radiology & Biomedical Imaging, University of California, San Francisco, California, USA., Pekmezci M; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Pathology, University of California, San Francisco, California, USA., Perry A; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Pathology, University of California, San Francisco, California, USA.; Department of Neurological Surgery, University of California, San Francisco, California, USA., Bollen AW; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Pathology, University of California, San Francisco, California, USA., Theodosopoulos PV; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Neurological Surgery, University of California, San Francisco, California, USA., Aghi MK; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Neurological Surgery, University of California, San Francisco, California, USA., Chang EF; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Neurological Surgery, University of California, San Francisco, California, USA., Hervey-Jumper SL; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Neurological Surgery, University of California, San Francisco, California, USA., Raleigh DR; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Pathology, University of California, San Francisco, California, USA.; Department of Neurological Surgery, University of California, San Francisco, California, USA.; Department of Radiation Oncology, University of California, San Francisco, California, USA., Molinaro AM; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Neurological Surgery, University of California, San Francisco, California, USA., Costello JF; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Neurological Surgery, University of California, San Francisco, California, USA., Diaz AA; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Neurological Surgery, University of California, San Francisco, California, USA., Clarke JL; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Division of Neuro-Oncology, Department of Neurological Surgery, University of California, San Francisco, California, USA.; Department of Neurology, University of California, San Francisco, California, USA., Butowski NA; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Division of Neuro-Oncology, Department of Neurological Surgery, University of California, San Francisco, California, USA., Phillips JJ; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Pathology, University of California, San Francisco, California, USA.; Department of Neurological Surgery, University of California, San Francisco, California, USA., Chang SM; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Division of Neuro-Oncology, Department of Neurological Surgery, University of California, San Francisco, California, USA., Berger MS; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Neurological Surgery, University of California, San Francisco, California, USA., Solomon DA; UCSF Brain Tumor Center, University of California, San Francisco, California, USA.; Department of Pathology, University of California, San Francisco, California, USA.

Publikováno v: Neuro-oncology [Neuro Oncol] 2024 Nov 19. Date of Electronic Publication: 2024 Nov 19.

Development and validation of a clinical risk model for postoperative outcome in newly diagnosed glioblastoma: a report of the RANO resect group.

Autor: Karschnia P; Department of Neurosurgery, LMU University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany.; Department of Neurosurgery, FAU University Hospital of the Friedrich-Alexander-University, Erlangen, Germany., Young JS; Department of Neurosurgery & Division of Neuro-Oncology, University of San Francisco, San Francisco, CA, USA., Youssef GC; Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Dono A; Department of Neurosurgery, McGovern Medical School at UT Health Houston, Houston, Texas, United States of America., Häni L; Department of Neurosurgery, Medical Center - University of Freiburg, Freiburg, Germany.; Department of Neurosurgery, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland., Sciortino T; Division of Neuro-Oncology, Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Bruno F; Division of Neuro-Oncology, Department of Neuroscience, University of Turin, Italy., Juenger ST; Department of Neurosurgery, University of Cologne, Cologne, Germany., Teske N; Department of Neurosurgery, LMU University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany.; Department of Neurosurgery, FAU University Hospital of the Friedrich-Alexander-University, Erlangen, Germany., Dietrich J; Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Weller M; Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland., Vogelbaum MA; Department of NeuroOncology, Moffitt Cancer Center, Tampa, Florida, United States of America., van den Bent M; Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Beck J; Department of Neurosurgery, Medical Center - University of Freiburg, Freiburg, Germany., Thon N; Department of Neurosurgery, LMU University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany., Gerritsen JKW; Department of Neurosurgery & Division of Neuro-Oncology, University of San Francisco, San Francisco, CA, USA.; Department of Neurosurgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Hervey-Jumper S; Department of Neurosurgery & Division of Neuro-Oncology, University of San Francisco, San Francisco, CA, USA., Cahill DP; Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Chang SM; Department of Neurosurgery & Division of Neuro-Oncology, University of San Francisco, San Francisco, CA, USA., Rudà R; Division of Neuro-Oncology, Department of Neuroscience, University of Turin, Italy., Bello L; Division of Neuro-Oncology, Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Schnell O; Department of Neurosurgery, FAU University Hospital of the Friedrich-Alexander-University, Erlangen, Germany.; Department of Neurosurgery, Medical Center - University of Freiburg, Freiburg, Germany., Esquenazi Y; Department of Neurosurgery, McGovern Medical School at UT Health Houston, Houston, Texas, United States of America., Ruge MI; Department of Stereotactic and Functional Neurosurgery, Centre of Neurosurgery, University of Cologne, Cologne, Germany., Grau SJ; Department of Neurosurgery, University of Cologne, Cologne, Germany.; Klinikum Fulda, Academic Hospital of Marburg University, Fulda, Germany., Huang RY; Division of Neuroradiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Berger MS; Department of Neurosurgery & Division of Neuro-Oncology, University of San Francisco, San Francisco, CA, USA., Molinaro AM; Department of Neurosurgery & Division of Neuro-Oncology, University of San Francisco, San Francisco, CA, USA., Tonn JC; Department of Neurosurgery, LMU University Hospital of the Ludwig-Maximilians-University Munich, Munich, Germany.; German Cancer Consortium (DKTK), Partner Site Munich, Germany.

Publikováno v: Neuro-oncology [Neuro Oncol] 2024 Nov 04. Date of Electronic Publication: 2024 Nov 04.